/ORMP
ORMP Stock - Oramed Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$2.93-1.68%
$0.05 (-1.68%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.73
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.22
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ORMP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.90 – $2.96
TARGET (TP)$3.37
STOP LOSS$2.70
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.17
52W High$3.20
52W Low$1.82
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.34M | $2.70M | $2.70M | $2.71M |
| Gross Profit | $-193,000 | $1.34M | $2.70M | $2.70M | $2.62M |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 96.7% |
| Operating Income | $-12,781,000 | $-15,769,000 | $-40,598,000 | $-24,223,000 | $-11,757,000 |
| Net Income | $-19,103,000 | $5.53M | $-37,764,000 | $-22,238,000 | $-11,511,000 |
| Net Margin | N/A | 412.3% | -1397.1% | -822.7% | -424.8% |
| EPS | $-0.47 | $0.14 | $-0.97 | $-0.78 | $-0.56 |
Company Overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
1
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish1 Neutral/Bearish
Price Targets
$3
Average Target
↑ 2.4% Upside
Now
$3
Low
$3
Average
$3
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 12th 2023 | Canaccord Genuity | Downgrade | Hold | $3← $30 |
Earnings History & Surprises
ORMPBeat Rate
53%
Last 19 quarters
Avg Surprise
-242.0%
EPS vs Estimate
Beats / Misses
10/8
1 met exactly
Latest EPS
$1.13
Q4 2025
EPS Surprise History
Q1 24
+33.3%
$-0.08vs$-0.12
Q2 24
+100.0%
$0.04vs$0.02
Q3 24
+2500.0%
$0.26vs$0.01
Q4 24
-9695.9%
$-0.48vs$-0.00
Q1 25
+133.3%
$0.01vs$-0.03
Q2 25
-533.3%
$-0.19vs$-0.03
Q3 25
-25.0%
$-0.05vs$-0.04
Q4 25
+2925.0%
$1.13vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.04 | $1.13 | +2925.0% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.03 | $-0.19 | -533.3% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.03 | $0.01 | +133.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.00 | $-0.48 | -9695.9% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $0.01 | $0.26 | +2500.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q1 2024 | Mar 6, 2024 | $-0.12 | $-0.08 | +33.3% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.11 | $-0.03 | +72.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.23 | $-0.08 | +65.2% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.22 | $-0.22 | 0.0% | = MET |
Q4 2022 | Nov 10, 2022 | $-0.26 | $-0.18 | +30.8% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.19 | $-0.27 | -41.9% | ✗ MISS |
Q1 2022 | Jan 11, 2022 | $-0.20 | $-0.22 | -10.0% | ✗ MISS |
Q4 2021 | Nov 24, 2021 | $-0.10 | $-0.21 | -110.0% | ✗ MISS |
Q3 2021 | Jul 14, 2021 | $-0.12 | $-0.17 | -41.7% | ✗ MISS |
Q2 2021 | Apr 13, 2021 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Latest News
Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M
📈 PositiveBenzinga•Nov 17, 2025, 01:58 PM
Oramed Advances Oral Insulin Program Independently; Announces Launch Of New U.S. Trial; Company Reaffirms Commitment To Rewarding Shareholders, Including Plans For One-Time Dividend
📈 PositiveBenzinga•Oct 23, 2025, 01:04 PM
Frequently Asked Questions about ORMP
What is ORMP's current stock price?
Oramed Pharmaceuticals Inc. (ORMP) is currently trading at $2.93 per share. The stock has moved -1.68% today.
What is the analyst price target for ORMP?
No analyst price targets are currently available for this stock.
What sector is Oramed Pharmaceuticals Inc. in?
Oramed Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ORMP's market cap?
Oramed Pharmaceuticals Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does ORMP pay dividends?
No, Oramed Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
CNTX
Context Therapeutics Inc.
$1.27
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
IMA
ImageneBio Inc
$6.18
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
Explore stocks similar to ORMP for comparison